Last reviewed · How we verify
Abacavir/Lamivudine
Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral replication by inhibiting conversion of viral RNA to DNA.
Abacavir and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block HIV reverse transcriptase, preventing viral replication by inhibiting conversion of viral RNA to DNA. Used for HIV-1 infection (as part of combination antiretroviral therapy).
At a glance
| Generic name | Abacavir/Lamivudine |
|---|---|
| Also known as | Kivexa, Epzicom, ABC/3TC, ABC/3TC placebo, efavirenz |
| Sponsor | GlaxoSmithKline |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Both drugs are nucleoside analogs that compete with natural nucleotides for incorporation into the growing DNA chain during reverse transcription. Once incorporated, they cause chain termination, effectively halting HIV replication. This combination is used as part of antiretroviral therapy to suppress viral load in HIV-infected patients.
Approved indications
- HIV-1 infection (as part of combination antiretroviral therapy)
Common side effects
- Hypersensitivity reaction (abacavir)
- Headache
- Nausea
- Diarrhea
- Fatigue
- Insomnia
- Lactic acidosis (rare)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study of GS-3242 in Participants With HIV-1; Substudy-05 (PHASE1)
- Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019 (PHASE3)
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Study of GS-1219 in Participants With HIV-1 (PHASE1)
- Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Abacavir/Lamivudine CI brief — competitive landscape report
- Abacavir/Lamivudine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI